The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism

Citations Over TimeTop 10% of 2014 papers

Abstract

Although multiple reports show that defective genetic networks underlie the aetiology of autism, few have translated into pharmacotherapeutic opportunities. Since drugs compete with endogenous small molecules for protein binding, many successful drugs target large gene families with multiple drug binding sites. Here we search for defective gene family interaction networks (GFINs) in 6,742 patients with the ASDs relative to 12,544 neurologically normal controls, to find potentially druggable genetic targets. We find significant enrichment of structural defects (P ≤ 2.40E-09, 1.8-fold enrichment) in the metabotropic glutamate receptor (GRM) GFIN, previously observed to impact attention deficit hyperactivity disorder (ADHD) and schizophrenia. Also, the MXD-MYC-MAX network of genes, previously implicated in cancer, is significantly enriched (P ≤ 3.83E-23, 2.5-fold enrichment), as is the calmodulin 1 (CALM1) gene interaction network (P ≤ 4.16E-04, 14.4-fold enrichment), which regulates voltage-independent calcium-activated action potentials at the neuronal synapse. We find that multiple defective gene family interactions underlie autism, presenting new translational opportunities to explore for therapeutic interventions.

Related Papers

• → Metabotropic Glutamate Receptor 5/Homer Interactions Underlie Stress Effects on Fear(2010)71 cited
• → Differential Binding of Calmodulin to Group I Metabotropic Glutamate Receptors Regulates Receptor Trafficking and Signaling(2011)47 cited
• → Mechanisms Associated with Activation of Intracellular Metabotropic Glutamate Receptor, mGluR5(2016)19 cited
• → Effects of metabotropic glutamate receptor ligands on male sexual behavior in rats(2012)13 cited
• Differential binding of calmodulin to group I metabotropic glutamate receptors regulates receptor trafficking and signaling(2011)